BioPharma Clinical Trials
Merck Launches Global Phase III Trial of Oral Cladribine for Generalized Myasthenia Gravis Treatment
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG) Cl...
September 06, 2024 | News
Antabio Completes Phase 1 Trial of MEM-ANT3310, Advancing Novel Antibacterial Treatment for Drug-Resistant Infections
Antabio, a private biopharmaceutical company developing novel and highly differentiated antibacterial treatments for critical priority pathogens, with a pa...
September 06, 2024 | News
Arsenal Biosciences Closes $325 Million Series C Funding to Advance Next-Gen CAR T-Cell Therapies for Solid Tumors
Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid t...
September 05, 2024 | News
GC Biopharma and Hanmi Pharmaceutical Receive FDA Clearance for Phase 1/2 Trial of First Once-Monthly Subcutaneous Treatment for Fabry Disease
Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" Improves efficacy co...
September 04, 2024 | News
Innovent Biologics Receives FDA Fast Track Designation for PD-1/IL-2α Bispecific Antibody in Advanced Melanoma Treatment
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...
September 04, 2024 | News
Simcere Zaiming and TargetRx Forge Strategic Partnership for Groundbreaking ALK/ROS1 Dual Inhibitor in China
Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx In...
September 03, 2024 | News
Nxera Pharma and Neurocrine Biosciences Report Positive Phase 2 Results for NBI-1117568 in Schizophrenia Treatment
Nxera Pharma – formerly known as Sosei Group or Sosei Heptares – notes the announcement by its partner Neurocrine Biosciences Inc. (&ldqu...
August 30, 2024 | News
Bayer Enrolls First Patient in Global Phase III SOHO-02 Trial Evaluating BAY 2927088 as First-Line Therapy for HER2-Mutant NSCLC
Bayer announced that the first patient has been enrolled in the global Phase III SOHO-02 trial, an open-label, randomized, multicenter clinical trial, asse...
August 30, 2024 | News
Merck Initiates Phase III MyClad Trial Dosing First Patient in Study of Oral Cladribine for Generalized Myasthenia Gravis
Merck, a leading science and technology company, announced the first patient has been dosed in the Phase III MyClad trial (NCT06463587) evaluating the effi...
August 30, 2024 | News
Yunovia Gains MFDS Clearance for Phase 1 MAD Study of Oral GLP-1 Agonist for Diabetes and Obesity
Yunovia, a drug R&D subsidiary of Ildong Pharmaceutical Group, announced on the 26th that the Ministry of Food and Drug Safety (MFDS) of Korea has clea...
August 28, 2024 | News
Shilpa Medicare Completes Phase 1 Trial for sRbumin®, India’s First Recombinant Human Albumin
Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship prod...
August 28, 2024 | News
Telix Pharmaceuticals Submits NDA to FDA for Innovative Brain Cancer Imaging Agent Pixclara®
Telix Pharmaceuticals announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for ...
August 28, 2024 | News
ArkBio CEO Presents Promising IPF Drug AK3280 at 8th Annual IPF Summit in Boston
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a privately held, clinical-stage biopharmaceutical company today announced that Dr. Jim Wu, Chief...
August 27, 2024 | News
Fujitsu Launches Major Initiative to Attract Global Clinical Trials to Japan, Tackling the Nation's 'Drug Loss' Issue
Fujitsu announced that it will begin initiatives to attract global clinical trials to Japan and tackle the ‘drug loss’ issue by working w...
August 26, 2024 | News
Most Read
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
